Statements (99)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:radio_station
|
| gptkbp:administered_by |
intravenous injection
|
| gptkbp:administration_setting |
outpatient or inpatient
|
| gptkbp:approves |
gptkb:2002
gptkb:European_Union gptkb:FDA gptkb:United_States |
| gptkbp:brand |
gptkb:Zevalin
|
| gptkbp:can_be_combined_with |
gptkb:rituximab
chemotherapy |
| gptkbp:clinical_trial |
Phase II
Phase III Phase I Zevalin in combination with chemotherapy Zevalin vs. Rituximab |
| gptkbp:clinical_use |
monotherapy or in combination with rituximab
|
| gptkbp:contraindication |
pregnancy
active infections lactation severe hypersensitivity to murine proteins severe bone marrow suppression hypersensitivity to ibritumomab tiuxetan |
| gptkbp:developed_by |
IDEC Pharmaceuticals
|
| gptkbp:dosage_form |
lyophilized powder
injectable solution |
| gptkbp:drug_interactions |
live vaccines
myelosuppressive drugs |
| gptkbp:duration |
single dose
multiple doses depends on treatment protocol |
| gptkbp:effective_date |
2002-02-25
|
| gptkbp:events |
monitor blood counts
monitor for infections assess response to treatment |
| gptkbp:financial_support |
gptkb:educational_resources
support groups financial assistance programs educational resources for patients support groups for lymphoma patients |
| https://www.w3.org/2000/01/rdf-schema#label |
Zevalin
|
| gptkbp:indication |
relapsed or refractory low-grade or follicular B-cell non-Hodgkin lymphoma
previously untreated follicular non-Hodgkin lymphoma non-Hodgkin's lymphoma |
| gptkbp:ingredients |
ibritumomab tiuxetan
|
| gptkbp:invention |
patented
generic available |
| gptkbp:manufacturer |
gptkb:Biogen_Idec
|
| gptkbp:market_position |
available
available in pharmacies available through specialty pharmacies |
| gptkbp:marketed_as |
gptkb:Biogen_Idec
Zevalin (ibritumomab tiuxetan) |
| gptkbp:mechanism_of_action |
targets CD20 antigen
targeting CD20 antigen |
| gptkbp:packaging |
single-use vial
|
| gptkbp:patient_education |
recognizing side effects
adherence to treatment schedule importance of follow-up appointments |
| gptkbp:patient_population |
gptkb:children
adults |
| gptkbp:pharmacokinetics |
monoclonal antibody conjugate
delivers radiation to CD20 positive cells |
| gptkbp:price |
high
varies by region and insurance |
| gptkbp:provides_guidance_on |
ASCO guidelines
NCCN guidelines ASCO guidelines for lymphoma NCCN guidelines for lymphoma |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:research |
Zevalin in combination with novel agents
Zevalin in elderly patients long-term outcomes of Zevalin therapy |
| gptkbp:research_areas |
gptkb:immunotherapy
oncology hematology |
| gptkbp:route_of_administration |
intravenous
IV infusion |
| gptkbp:service_frequency |
once per treatment cycle
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:disease
fatigue nausea fever vomiting rash thrombocytopenia infusion reactions neutropenia myelosuppression |
| gptkbp:storage |
refrigerated
refrigerated at 2-8° C |
| gptkbp:structure |
gptkb:isotope
gptkb:monoclonal_antibody |
| gptkbp:treatment |
gptkb:monoclonal_antibody
|
| gptkbp:used_for |
gptkb:Oncology
treatment of non-Hodgkin lymphoma |
| gptkbp:bfsParent |
gptkb:Idec_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|